Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 331

1.

Epigenomic profiling reveals an association between persistence of DNA methylation and metabolic memory in the DCCT/EDIC type 1 diabetes cohort.

Chen Z, Miao F, Paterson AD, Lachin JM, Zhang L, Schones DE, Wu X, Wang J, Tompkins JD, Genuth S, Braffett BH, Riggs AD; DCCT/EDIC Research Group., Natarajan R.

Proc Natl Acad Sci U S A. 2016 May 24;113(21):E3002-11. doi: 10.1073/pnas.1603712113.

2.

Glycemic Control and Urinary Tract Infections in Women with Type 1 Diabetes: Results from the DCCT/EDIC.

Lenherr SM, Clemens JQ, Braffett BH, Cleary PA, Dunn RL, Hotaling JM, Jacobson AM, Kim C, Herman W, Brown JS, Wessells H, Sarma AV; DCCT/EDIC Research Group..

J Urol. 2016 Oct;196(4):1129-35. doi: 10.1016/j.juro.2016.04.071.

3.

Effect of adding insulin degludec to treatment in patients with type 2 diabetes inadequately controlled with metformin and liraglutide: a double-blind randomized controlled trial (BEGIN: ADD TO GLP-1 Study).

Aroda VR, Bailey TS, Cariou B, Kumar S, Leiter LA, Raskin P, Zacho J, Andersen TH, Philis-Tsimikas A.

Diabetes Obes Metab. 2016 Jul;18(7):663-70. doi: 10.1111/dom.12661. Erratum in: Diabetes Obes Metab. 2016 Sep;18(9):952.

4.

AMG 151 (ARRY-403), a novel glucokinase activator, decreases fasting and postprandial glycaemia in patients with type 2 diabetes.

Katz L, Manamley N, Snyder WJ, Dodds M, Agafonova N, Sierra-Johnson J, Cruz M, Kaur P, Mudaliar S, Raskin P, Kewalramani R, Pellacani A.

Diabetes Obes Metab. 2016 Feb;18(2):191-5. doi: 10.1111/dom.12586.

PMID:
26434934
5.

Use of Dried Capillary Blood Sampling for Islet Autoantibody Screening in Relatives: A Feasibility Study.

Bingley PJ, Rafkin LE, Matheson D, Steck AK, Yu L, Henderson C, Beam CA, Boulware DC; TrialNet Study Group..

Diabetes Technol Ther. 2015 Dec;17(12):867-71. doi: 10.1089/dia.2015.0133.

6.

Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.

Bakris GL, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, Remuzzi G, Rossing P, Schmieder RE, Nowack C, Kolkhof P, Joseph A, Pieper A, Kimmeskamp-Kirschbaum N, Ruilope LM; Mineralocorticoid Receptor Antagonist Tolerability Study–Diabetic Nephropathy (ARTS-DN) Study Group..

JAMA. 2015 Sep 1;314(9):884-94. doi: 10.1001/jama.2015.10081.

PMID:
26325557
7.

Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients.

Rigby MR, Harris KM, Pinckney A, DiMeglio LA, Rendell MS, Felner EI, Dostou JM, Gitelman SE, Griffin KJ, Tsalikian E, Gottlieb PA, Greenbaum CJ, Sherry NA, Moore WV, Monzavi R, Willi SM, Raskin P, Keyes-Elstein L, Long SA, Kanaparthi S, Lim N, Phippard D, Soppe CL, Fitzgibbon ML, McNamara J, Nepom GT, Ehlers MR.

J Clin Invest. 2015 Aug 3;125(8):3285-96. doi: 10.1172/JCI81722.

8.

Caffeine Consumption Contributes to Skin Intrinsic Fluorescence in Type 1 Diabetes.

Eny KM, Orchard TJ, Miller RG, Maynard J, Grant DM, Costacou T, Cleary PA, Braffett BH, Paterson AD; DCCT/EDIC Research Group..

Diabetes Technol Ther. 2015 Oct;17(10):726-34. doi: 10.1089/dia.2015.0017.

10.

Pregabalin in Patients With Painful Diabetic Peripheral Neuropathy Using an NSAID for Other Pain Conditions: A Double-Blind Crossover Study.

Raskin P, Huffman C, Yurkewicz L, Pauer L, Scavone JM, Yang R, Parsons B.

Clin J Pain. 2016 Mar;32(3):203-10. doi: 10.1097/AJP.0000000000000254.

PMID:
25968451
11.

Intensive diabetes therapy and ocular surgery in type 1 diabetes.

DCCT/EDIC Research Group., Aiello LP, Sun W, Das A, Gangaputra S, Kiss S, Klein R, Cleary PA, Lachin JM, Nathan DM.

N Engl J Med. 2015 Apr 30;372(18):1722-33. doi: 10.1056/NEJMoa1409463.

12.

The development and utility of a novel scale that quantifies the glycemic progression toward type 1 diabetes over 6 months.

Sosenko JM, Skyler JS, Beam CA, Boulware D, Mahon JL, Krischer JP, Greenbaum CJ, Rafkin LE, Matheson D, Herold KC, Palmer JP; Type 1 Diabetes TrialNet and Diabetes Prevention Trial–Type 1 Study Groups..

Diabetes Care. 2015 May;38(5):940-2. doi: 10.2337/dc14-2787.

13.

Fine mapping of type 1 diabetes susceptibility loci and evidence for colocalization of causal variants with lymphoid gene enhancers.

Onengut-Gumuscu S, Chen WM, Burren O, Cooper NJ, Quinlan AR, Mychaleckyj JC, Farber E, Bonnie JK, Szpak M, Schofield E, Achuthan P, Guo H, Fortune MD, Stevens H, Walker NM, Ward LD, Kundaje A, Kellis M, Daly MJ, Barrett JC, Cooper JD, Deloukas P; Type 1 Diabetes Genetics Consortium., Todd JA, Wallace C, Concannon P, Rich SS.

Nat Genet. 2015 Apr;47(4):381-6. doi: 10.1038/ng.3245.

14.

A new approach for diagnosing type 1 diabetes in autoantibody-positive individuals based on prediction and natural history.

Sosenko JM, Skyler JS, DiMeglio LA, Beam CA, Krischer JP, Greenbaum CJ, Boulware D, Rafkin LE, Matheson D, Herold KC, Mahon J, Palmer JP; Type 1 Diabetes TrialNet Study Group.; Diabetes Prevention Trial-Type 1 Study Group..

Diabetes Care. 2015 Feb;38(2):271-6. doi: 10.2337/dc14-1813.

15.

Genome-wide meta-analysis of myopia and hyperopia provides evidence for replication of 11 loci.

Simpson CL, Wojciechowski R, Oexle K, Murgia F, Portas L, Li X, Verhoeven VJ, Vitart V, Schache M, Hosseini SM, Hysi PG, Raffel LJ, Cotch MF, Chew E, Klein BE, Klein R, Wong TY, van Duijn CM, Mitchell P, Saw SM, Fossarello M, Wang JJ; DCCT/EDIC Research Group., Polašek O, Campbell H, Rudan I, Oostra BA, Uitterlinden AG, Hofman A, Rivadeneira F, Amin N, Karssen LC, Vingerling JR, Döring A, Bettecken T, Bencic G, Gieger C, Wichmann HE, Wilson JF, Venturini C, Fleck B, Cumberland PM, Rahi JS, Hammond CJ, Hayward C, Wright AF, Paterson AD, Baird PN, Klaver CC, Rotter JI, Pirastu M, Meitinger T, Bailey-Wilson JE, Stambolian D.

PLoS One. 2014 Sep 18;9(9):e107110. doi: 10.1371/journal.pone.0107110.

16.

Poor glycemic control is associated with reduced prostate specific antigen concentrations in men with type 1 diabetes.

Sarma AV, Hotaling J, Dunn RL, Cleary PA, Braffett BH, Kim C, Martin C, Herman W, Gatcomb P, Jacobson AM, Holt SK, Wessells H; DCCT/EDIC Research Group..

J Urol. 2015 Mar;193(3):786-93. doi: 10.1016/j.juro.2014.08.115.

17.

Rationale and design of the Vitamin D and Type 2 Diabetes (D2d) study: a diabetes prevention trial.

Pittas AG, Dawson-Hughes B, Sheehan PR, Rosen CJ, Ware JH, Knowler WC, Staten MA; D2d Research Group..

Diabetes Care. 2014 Dec;37(12):3227-34. doi: 10.2337/dc14-1005.

18.

Exenatide extended-release: a once weekly treatment for patients with type 2 diabetes.

Mann KV, Raskin P.

Diabetes Metab Syndr Obes. 2014 Jun 24;7:229-39. doi: 10.2147/DMSO.S35331. Review.

19.

Consensus Statement by the American Association of Clinical Endocrinologists/American College of Endocrinology insulin pump management task force.

Grunberger G, Abelseth JM, Bailey TS, Bode BW, Handelsman Y, Hellman R, Jovanovič L, Lane WS, Raskin P, Tamborlane WV, Rothermel C.

Endocr Pract. 2014 May;20(5):463-89. doi: 10.4158/EP14145.PS. No abstract available.

PMID:
24816754
20.

Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial.

Rigby MR, DiMeglio LA, Rendell MS, Felner EI, Dostou JM, Gitelman SE, Patel CM, Griffin KJ, Tsalikian E, Gottlieb PA, Greenbaum CJ, Sherry NA, Moore WV, Monzavi R, Willi SM, Raskin P, Moran A, Russell WE, Pinckney A, Keyes-Elstein L, Howell M, Aggarwal S, Lim N, Phippard D, Nepom GT, McNamara J, Ehlers MR; T1DAL Study Team..

Lancet Diabetes Endocrinol. 2013 Dec;1(4):284-94. doi: 10.1016/S2213-8587(13)70111-6.

Items per page

Supplemental Content

Loading ...
Support Center